

Howard Cuckle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8354148/publications.pdf>

Version: 2024-02-01

166
papers

6,385
citations

61984

43
h-index

74163

75
g-index

172
all docs

172
docs citations

172
times ranked

3588
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. <i>Lancet, The</i> , 2006, 368, 2053-2060.	13.7	434
2	Noninvasive prenatal testing for aneuploidy: current status and future prospects. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 15-33.	1.7	282
3	Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. <i>Lancet, The</i> , 1977, 1, 1323-32.	13.7	257
4	Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort. <i>Obstetrics and Gynecology</i> , 2014, 124, 210-218.	2.4	254
5	Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. <i>Prenatal Diagnosis</i> , 2015, 35, 725-734.	2.3	243
6	Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. <i>Health Technology Assessment</i> , 2004, 8, iii, ix-x, 1-109.	2.8	228
7	Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. <i>Prenatal Diagnosis</i> , 2013, 33, 622-629.	2.3	181
8	Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. <i>Lancet Oncology, The</i> , 2015, 16, 1123-1132.	10.7	159
9	Maternal age-specific risks for trisomies at 9-14 weeks' gestation. <i>Prenatal Diagnosis</i> , 1994, 14, 543-552.	2.3	145
10	Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. <i>Prenatal Diagnosis</i> , 2004, 24, 762-766.	2.3	132
11	Appropriate biochemical parameters in first-trimester screening for Down syndrome. <i>Prenatal Diagnosis</i> , 1999, 19, 505-512.	2.3	128
12	Contingent screening for Down syndrome—results from the FaSTER trial. <i>Prenatal Diagnosis</i> , 2008, 28, 89-94.	2.3	119
13	Screening for fragile X syndrome in women of reproductive age. <i>Prenatal Diagnosis</i> , 2000, 20, 611-614.	2.3	117
14	Down Syndrome Screening in the First and/or Second Trimester: Model Predicted Performance Using Meta-Analysis Parameters. <i>Seminars in Perinatology</i> , 2005, 29, 252-257.	2.5	111
15	Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. <i>Lancet Oncology, The</i> , 2020, 21, 1165-1172.	10.7	110
16	Role of Second-Trimester Genetic Sonography After Down Syndrome Screening. <i>Obstetrics and Gynecology</i> , 2009, 114, 1189-1196.	2.4	104
17	Maternal cfDNA screening for Down syndrome—a cost sensitivity analysis. <i>Prenatal Diagnosis</i> , 2013, 33, 636-642.	2.3	102
18	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1991, 98, 905-908.	2.3	98

#	ARTICLE	IF	CITATIONS
19	Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. American Journal of Obstetrics and Gynecology, 2006, 195, 1379-1387.	1.3	88
20	Down's syndrome screening in twins. Journal of Medical Screening, 1998, 5, 3-4.	2.3	87
21	Biochemical screening for Down syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2000, 92, 97-101.	1.1	85
22	Frequency of Down's syndrome and neural-tube defects in the same family. Lancet, The, 2003, 361, 1331-1335.	13.7	83
23	THE EFFECT OF MATERNAL WEIGHT ON MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS. BJOG: an International Journal of Obstetrics and Gynaecology, 1981, 88, 1094-1096.	2.3	81
24	Co-variables in first trimester maternal serum screening. Prenatal Diagnosis, 2000, 20, 186-189.	2.3	77
25	Cell-free DNA screening for fetal aneuploidy as a clinical service. Clinical Biochemistry, 2015, 48, 932-941.	1.9	75
26	SMALL BIPARIETAL DIAMETER OF FETUSES WITH SPINA BIFIDA: IMPLICATIONS FOR ANTENATAL SCREENING. BJOG: an International Journal of Obstetrics and Gynaecology, 1980, 87, 219-221.	2.3	74
27	Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. , 1999, 19, 458-462.		73
28	Improved parameters for risk estimation in Down's syndrome screening. Prenatal Diagnosis, 1995, 15, 1057-1065.	2.3	72
29	Reporting the assessment of screening and diagnostic tests. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 389-396.	2.3	68
30	Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasma. Prenatal Diagnosis, 2014, 34, 778-783.	2.3	67
31	First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenatal Diagnosis, 2005, 25, 901-905.	2.3	66
32	Time for total shift to first-trimester screening for Down's syndrome. Lancet, The, 2001, 358, 1658-1659.	13.7	57
33	Integrating antenatal Down's syndrome screening. Current Opinion in Obstetrics and Gynecology, 2001, 13, 175-181.	2.0	56
34	Use of videotapes for viewing at home to inform choice in Down syndrome screening: a randomised controlled trial. Prenatal Diagnosis, 2001, 21, 146-149.	2.3	56
35	Impact of the COVID-19 Pandemic on Excess Perinatal Mortality and Morbidity in Israel. American Journal of Perinatology, 2021, 38, 398-403.	1.4	56
36	Birth prevalence of down's syndrome in England and Wales. Prenatal Diagnosis, 1991, 11, 29-34.	2.3	55

#	ARTICLE	IF	CITATIONS
37	Established markers in second trimester maternal serum. <i>Early Human Development</i> , 1996, 47, S27-S29.	1.8	55
38	Development of prenatal screening—A historical overview. <i>Seminars in Perinatology</i> , 2016, 40, 12-22.	2.5	55
39	Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy. <i>Prenatal Diagnosis</i> , 1993, 13, 633-636.	2.3	52
40	Second trimester ultrasound prenatal thickness combined with nasal bone length: a new method of Down syndrome screening. <i>Prenatal Diagnosis</i> , 2005, 25, 906-911.	2.3	52
41	Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9–12 weeks' gestation. <i>Prenatal Diagnosis</i> , 2006, 26, 689-691.	2.3	52
42	Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. <i>Prenatal Diagnosis</i> , 2011, 31, 519-522.	2.3	51
43	Age-standardisation when target setting and auditing performance of Down syndrome screening programmes. <i>Prenatal Diagnosis</i> , 2004, 24, 851-856.	2.3	50
44	First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. <i>Prenatal Diagnosis</i> , 2003, 23, 833-836.	2.3	48
45	Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1992, 99, 51-53.	2.3	44
46	Down syndrome fetal loss rate in early pregnancy. , 1999, 19, 1177-1179.		43
47	Decisions About Testing and Termination of Pregnancy for Different Fetal Conditions: A Qualitative Study of European White and Pakistani Mothers of Affected Children. <i>Journal of Genetic Counseling</i> , 2008, 17, 560-572.	1.6	40
48	First-trimester detection of major cardiac defects with the use of ductus venosus blood flow. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 51-57.	1.7	40
49	8 Recent advances in screening for neural tube defects and Down's syndrome. <i>Bailliere's Clinical Obstetrics and Gynaecology</i> , 1987, 1, 649-676.	0.6	38
50	Ultrasound fetal femur length measurement in the screening for Down's syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1989, 96, 1373-1378.	2.3	38
51	First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free human chorionic gonadotrophin, placental growth factor, and β -fetoprotein. <i>Prenatal Diagnosis</i> , 2015, 35, 709-716.	2.3	38
52	Down's syndrome screening with nuchal translucency at 12+0-14+0 weeks and maternal serum markers at 14+1-17+0 weeks: a prospective study. <i>Human Reproduction</i> , 2002, 17, 1093-1098.	0.9	37
53	Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. <i>Prenatal Diagnosis</i> , 2003, 23, 389-392.	2.3	36
54	Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 223.e1-223.e5.	1.3	36

#	ARTICLE	IF	CITATIONS
55	Familial Down syndrome: evidence supporting cytoplasmic inheritance. <i>Clinical Genetics</i> , 2002, 60, 456-462.	2.0	34
56	Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy. <i>Prenatal Diagnosis</i> , 1994, 14, 321-322.	2.3	32
57	Pregnancy associated plasma protein A in Down's syndrome.. <i>BMJ: British Medical Journal</i> , 1992, 305, 425-425.	2.3	29
58	First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. <i>Prenatal Diagnosis</i> , 2013, 33, 1044-1049.	2.3	29
59	Model-Predicted Performance of Second-Trimester Down Syndrome Screening With Sonographic Prenasal Thickness. <i>Journal of Ultrasound in Medicine</i> , 2010, 29, 1741-1747.	1.7	28
60	AFP and age screening for down syndrome. <i>American Journal of Medical Genetics Part A</i> , 1988, 31, 197-209.	2.4	27
61	Maternal serum placental growth factor and β -fetoprotein testing in first trimester screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2013, 33, 457-461.	2.3	26
62	Increase rate of ruptured tubal ectopic pregnancy during the COVID-19 pandemic. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 259, 95-99.	1.1	26
63	Combining fetal nuchal fold thickness with second-trimester biochemistry to screen for trisomy 21. <i>Ultrasound in Obstetrics and Gynecology</i> , 2007, 30, 941-945.	1.7	25
64	Maternal serum human chorionic gonadotrophin levels in systemic lupus erythematosus and antiphospholipid syndrome. <i>Prenatal Diagnosis</i> , 2001, 21, 143-145.	2.3	24
65	Down syndrome risk calculation for a twin fetus taking account of the nuchal translucency in the co-twin. <i>Prenatal Diagnosis</i> , 2010, 30, 827-833.	2.3	24
66	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-24.	2.8	23
67	Nuchal Translucency Quality Review (NTQR) program: first one and half million results. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 199-204.	1.7	22
68	Correlation between nuchal translucency and nuchal skin-fold measurements in Down syndrome and unaffected fetuses. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 501-505.	1.7	21
69	Bedside estimation of Down syndrome risk from second-trimester ultrasound prenatal thickness. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 629-633.	1.7	21
70	Antenatal screening for cystic fibrosis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1996, 103, 795-799.	2.3	20
71	Screening for Cystic Fibrosis. <i>Disease Management and Health Outcomes</i> , 1998, 3, 161-172.	0.4	20
72	Frequency and clinical consequences of extremely high maternal serum PAPP-A levels. <i>Prenatal Diagnosis</i> , 2003, 23, 385-388.	2.3	20

#	ARTICLE	IF	CITATIONS
73	Collaborative study of maternal urine β -core human chorionic gonadotrophin screening for Down syndrome. , 1999, 19, 911-917.		19
74	First- and second-trimester maternal serum markers of pre-eclampsia in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2016, 47, 560-564.	1.7	18
75	Taking account of vaginal bleeding in screening for Down's syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 1994, 101, 948-952.	2.3	17
76	Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates?. Prenatal Diagnosis, 2002, 22, 903-906.	2.3	17
77	Primary prevention of Down's syndrome. International Journal of Medical Sciences, 2005, 2, 93-99.	2.5	17
78	ADAM12s as a first-trimester screening marker of trisomy. Prenatal Diagnosis, 2009, 29, 866-869.	2.3	17
79	Monitoring Quality Control of Nuchal Translucency. Clinics in Laboratory Medicine, 2010, 30, 593-604.	1.4	17
80	Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing. Obstetrics and Gynecology, 2012, 119, 1270.	2.4	17
81	Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy. Clinical Proteomics, 2015, 12, 9.	2.1	17
82	Maternal age-standardisation of prevalence of Down's syndrome. Lancet, The, 1999, 354, 529-530.	13.7	15
83	Model predicted Down syndrome detection rates for nuchal translucency screening in twin pregnancies. Prenatal Diagnosis, 2011, 31, 426-429.	2.3	15
84	Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins. PLoS ONE, 2020, 15, e0233214.	2.5	15
85	Down syndrome screening marker levels in women with a previous aneuploidy pregnancy. Prenatal Diagnosis, 2005, 25, 47-50.	2.3	14
86	Serum matrix metalloproteinase-9 in Down's syndrome pregnancies. Human Reproduction, 2007, 22, 1017-1020.	0.9	14
87	Screening for Down syndrome – incidental diagnosis of other aneuploidies. Prenatal Diagnosis, 2014, 34, 1044-1048.	2.3	14
88	Tests using single markers. , 2000, , 3-22.		14
89	Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening. Prenatal Diagnosis, 2005, 25, 1102-1106.	2.3	13
90	Prenatal Screening Using Maternal Markers. Journal of Clinical Medicine, 2014, 3, 504-520.	2.4	13

#	ARTICLE	IF	CITATIONS
91	<scp>cfDNA</scp> screening performance: accounting for and reducing test failures. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 689-692.	1.7	13
92	Maternal age in the epidemiology of common autosomal trisomies. <i>Prenatal Diagnosis</i> , 2021, 41, 573-583.	2.3	13
93	Maternal serum thyroid antibodies in early pregnancy and fetal Down's syndrome. <i>Prenatal Diagnosis</i> , 1988, 8, 439-445.	2.3	12
94	Spina bifida screening in the first trimester using ultrasound biparietal diameter measurement adjusted for crown-€rump length or abdominal circumference. <i>Prenatal Diagnosis</i> , 2019, 39, 314-318.	2.3	12
95	Early pregnancy prediction of spontaneous preterm birth before 32 completed weeks of pregnancy using plasma RNA: transcriptome discovery and initial validation of an RNA panel of markers. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1870-1880.	2.3	12
96	Detection of Î²-core fragment in second trimester Down's syndrome pregnancies. <i>Early Human Development</i> , 1996, 47, S47-S48.	1.8	11
97	Maternal serum PlGF (placental growth factor) in Chinese women in the first trimester undergoing screening for Down syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 201, 166-170.	1.1	11
98	Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome. , 2000, 20, 12-16.		10
99	Aneuploidy Screening. <i>Obstetrics and Gynecology</i> , 2006, 107, 715-718.	2.4	10
100	Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies. <i>Prenatal Diagnosis</i> , 2008, 28, 904-907.	2.3	10
101	Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18. <i>Prenatal Diagnosis</i> , 2011, 31, 33-37.	2.3	10
102	Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis. <i>Obstetrics and Gynecology</i> , 2020, 135, 217-217.	2.4	10
103	Implementation of a National Nuchal Translucency Education and Quality Monitoring Program. <i>Obstetrics and Gynecology</i> , 2014, 123, 149-154.	2.4	9
104	Potential biases in Down syndrome birth prevalence estimation. <i>Journal of Medical Screening</i> , 2002, 9, 192-192.	2.3	8
105	Performance adjusted risks: a method to improve the quality of algorithm performance while allowing all to play. <i>Prenatal Diagnosis</i> , 2011, 31, 797-801.	2.3	8
106	Clinical utility and cost of non-invasive prenatal testing. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 320-321.	1.5	8
107	Review of epidemiological factors (other than maternal age) that determine the prevalence of common autosomal trisomies. <i>Prenatal Diagnosis</i> , 2021, 41, 536-544.	2.3	8
108	Maternal serum inhibin levels in twin and singleton pregnancies conceived by assisted reproduction. <i>Human Reproduction</i> , 2006, 21, 1305-1308.	0.9	7

#	ARTICLE	IF	CITATIONS
109	Role of secondâ€trimester ultrasound in screening for Down syndrome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 241-244.	1.7	7
110	Cost-Effectiveness of First Trimester Screening for Preterm Pre-eclampsia in Lebanon. <i>Journal of Fetal Medicine</i> , 2020, 7, 119-123.	0.1	7
111	Cellâ€free DNA screening for fetal aneuploidy using the rolling circle method: a step towards NIPT simplification. <i>Prenatal Diagnosis</i> , 2021, , .	2.3	7
112	Consequences of imprecision in fetal fraction estimation on performance of cellâ€free DNA screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2022, , .	2.3	7
113	Biochemical screening for aneuploidy. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 765-773.	0.4	6
114	Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, 190.	2.4	6
115	Biochemical and ultrasound screening for Down's syndrome: rivals or partners?. <i>Ultrasound in Obstetrics and Gynecology</i> , 1996, 7, 236-238.	1.7	5
116	Nuchal translucency screening in triplets: Down syndrome risk calculation taking account of betweenâ€fetus correlations. <i>Prenatal Diagnosis</i> , 2012, 32, 214-219.	2.3	5
117	Rational and irrational ratios. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 48, 275-278.	1.7	5
118	Incorporating thyroid markers in Down syndrome screening protocols. <i>Prenatal Diagnosis</i> , 2017, 37, 510-514.	2.3	5
119	Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component. , 2000, 20, 395-399.		4
120	Case report: clinical utility of ultrasound nasal bone determination in the prenatal diagnosis of Down syndrome. <i>Prenatal Diagnosis</i> , 2003, 23, 433-434.	2.3	4
121	Noninvasive Prenatal Testing and Fetal Sonographic Screening. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 363-369.	1.7	4
122	Enhanced First Trimester Aneuploidy Screening with Placental Growth Factor and Alpha Feto-Protein: Detection of Trisomies 18 and 13. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 1295-1301.	0.7	4
123	Downâ€™s syndrome screening at 11â€14 weeks' gestation using prenatal thickness and nasal bone length. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 939-945.	1.7	4
124	Local validation and calibration of preâ€eclampsia screening algorithms. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 724-728.	1.7	4
125	Aneuploidy indices in biochemical screening. <i>Prenatal Diagnosis</i> , 1992, 12, 545-545.	2.3	3
126	Principles of screening. <i>The Obstetrician and Gynaecologist</i> , 2004, 6, 21-25.	0.4	3

#	ARTICLE	IF	CITATIONS
127	Suboptimal Down syndrome screening test interpretation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2005, 27, 6-8.	1.7	3
128	Extrapolation of maternal weight in sequential aneuploidy screening. <i>Prenatal Diagnosis</i> , 2014, 34, 753-758.	2.3	3
129	Strategies for Implementing Cell-Free DNA Testing. <i>Clinics in Laboratory Medicine</i> , 2016, 36, 213-226.	1.4	3
130	Bedside risk estimation of morbidly adherent placenta using simple calculator. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 631-635.	1.7	3
131	Oligohydramnios: how severe is severe?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 5754-5760.	1.5	3
132	Evaluation of a Maternal Plasma RNA Panel Predicting Spontaneous Preterm Birth and Its Expansion to the Prediction of Preeclampsia. <i>Diagnostics</i> , 2022, 12, 1327.	2.6	3
133	CT ratios: parameter estimates are inconsistent with SURUSS publications?. <i>Prenatal Diagnosis</i> , 2006, 26, 991-992.	2.3	2
134	Steering the Course Between Optimal Policies and Practical Restraints. <i>Journal of Fetal Medicine</i> , 2014, 1, 3-5.	0.1	2
135	Rethinking secondâ€trimester Downâ€syndrome screening in the cellâ€free DNA era. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 431-436.	1.7	2
136	Epidemiology and Genetics of Human Aneuploidy. , 2019, , 529-551.		2
137	Downâ€s Syndrome Screening in the First Trimester with Additional Serum Markers: Indian Parameters. <i>Journal of Obstetrics and Gynecology of India</i> , 2020, 70, 12-17.	0.9	2
138	Coâ€variables in first trimester maternal serum screening. <i>Prenatal Diagnosis</i> , 2000, 20, 186-189.	2.3	2
139	Cost of providing cell-free DNA screening for Down syndrome in Finland using different strategies. <i>Journal of Perinatal Medicine</i> , 2022, 50, 233-243.	1.4	2
140	Absence of nasal bone and detection of trisomy 21. <i>Lancet, The</i> , 2002, 359, 1345.	13.7	1
141	A matter of opinion of evidence!. <i>Prenatal Diagnosis</i> , 2006, 26, 1184-1184.	2.3	1
142	Prenatal Screening Strategies in Localities with Limited Resources. <i>Journal of Fetal Medicine</i> , 2017, 4, 165-170.	0.1	1
143	Re: Cutâ€off value of nuchal translucency as indication for chromosomal microarray analysis. I. Maya, S. Yacobson, S. Kahana, J. Yeshaya, T. Tenne, I. Agmonâ€Fishman, L. Cohenâ€Vig, M. Shohat, L. Baselâ€Vanagaite and R. Sharony. <i>Ultrasound Obstet Gynecol</i> 2017; 50: 332â€335.. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 293-294.	1.7	1
144	The mid-gestation triple test profile among women diagnosed with vasa previa. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018, 31, 1402-1406.	1.5	1

#	ARTICLE	IF	CITATIONS
145	First-trimester Abdominal Circumference (Versus Crown Rump Length) Improves Precision in Inter- and Intraobserver Variability. <i>Journal of Ultrasound in Medicine</i> , 2019, 38, 2161-2167.	1.7	1
146	Maternal weight as an additional first trimester spina bifida screening marker. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 3353-3358.	1.5	1
147	Screening for early-onset preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 246.	1.3	1
148	The United States' experience in nuchal translucency: variation by provider characteristics in over 5 million ultrasound measurements. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 732-737.	1.7	1
149	The origins of aneuploidy research consortium. <i>Prenatal Diagnosis</i> , 2021, 41, 642-646.	2.3	1
150	Should CVS or amniocentesis be performed in RPL without screening?. <i>Series in Maternal-fetal Medicine</i> , 2007, , 55-58.	0.1	1
151	Re: Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma <sc>protein A</sc> or placental growth factor?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 404-404.	1.7	1
152	Quality assessment of first-trimester screening for preterm pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 60, 746-750.	1.7	1
153	First trimester Down syndrome screening markers in triploidy: a case report. , 1999, 19, 1086-1088.		0
154	Serum Expression of Sialyltransferase in Normal and Down's Syndrome-Affected Pregnancy. <i>Annals of Clinical Biochemistry</i> , 2000, 37, 507-511.	1.6	0
155	Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. <i>Journal of Obstetrics and Gynaecology</i> , 2003, 23, S37-S37.	0.9	0
156	Which contingent sequential screening protocol?: A response. <i>Prenatal Diagnosis</i> , 2005, 25, 1169-1170.	2.3	0
157	Pathogenesis and Etiology of Down's Syndrome in Relation to Oxidative Stress. , 2006, , 557-576.		0
158	OC02.01: Nuchal Translucency Education and Quality Review (NTQR) program: first one million results. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 3-3.	1.7	0
159	OC08.06: Accuracy and precision of crown-rump length and other fetal biometry in nuchal translucency screening interpretation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 16-16.	1.7	0
160	OP11.03: Intra- and inter-observer variability of crown-rump length and other fetal biometry at the nuchal translucency scan. <i>Ultrasound in Obstetrics and Gynecology</i> , 2011, 38, 87-87.	1.7	0
161	Re: Repeat measurements of nuchal translucency at 11-14 weeks of gestation: when do we need them? L. J. Salomon, R. Porcher, D. Socolov, H. Lamrani and Y. Ville. <i>Ultrasound Obstet Gynecol</i> 2013; 42: 629-633. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 613-613.	1.7	0
162	Maternal Urine Screening for Down Syndrome: Past Studies and Future Perspectives. <i>Journal of Fetal Medicine</i> , 2016, 3, 149-150.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Reply. Ultrasound in Obstetrics and Gynecology, 2017, 49, 158-158.	1.7	0
164	Ultrasound and Biochemical Screening for Fetal Aneuploidy. , 2020, , 161-175.e3.		0
165	Pre-eclampsia screening studies “overcoming intervention bias. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, , .	2.3	0
166	Cystic fibrosis screening strategies. British Journal of Hospital Medicine, 1993, 50, 398-402.	0.0	0